Cancer

mPATH Health in the Spotlight as Part of the NCI Investor Initiatives Program

Winston-Salem based digital health company will showcase its technology at world-famous HLTH Conference WINSTON-SALEM, N.C., Oct. 14, 2024 /PRNewswire/ -- mPATH®…

1 year ago

Rural Hospitals Strengthen Care and Finances by Embracing Data-Driven Solutions

FARMINGTON, Utah, Oct. 14, 2024 /PRNewswire/ -- REDi Health Analytics, LLC ("REDi Health") partnered with a state health department to…

1 year ago

21st TAITA Annual Conference Explores Taiwan’s AI Era Strategies in the Global Tech Supply Chain

TAIPEI, Oct. 13, 2024 /PRNewswire/ -- The upcoming 21st TAITA-SV Annual Conference, scheduled for Saturday, October 19, 2024, at the…

1 year ago

Quest PharmaTech Announces Results from AGM

EDMONTON, Alberta, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V:QPT) (“Quest” or the “Company”) today announced the results…

1 year ago

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

Boca Raton, Florida, Oct. 11, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and…

1 year ago

Auron Announces Poster Presentation at 2024 PCF Annual Scientific Retreat

NEWTON, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by…

1 year ago

Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway

Realigning resources to focus on clinical advancement of Selected TIL therapyReducing employee headcount by approximately 60%Streamlining operations with cash runway…

1 year ago

Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio

MEDIA RELEASE First FDA-approved abbreviated new drug application (ANDA) to reference medicineSingle-dose 100 mg vial for intravenous use, approved for…

1 year ago

FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Approval is based on Phase III INAVO120 results, showing the Itovebi™ (inavolisib)-based regimen more than doubled progression-free survival compared with…

1 year ago